Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.

Antimicrobial Agents and Chemotherapy
Russell E LewisDimitrios P Kontoyiannis

Abstract

In a neutropenic murine model of invasive pulmonary aspergillosis, prophylaxis with single doses of liposomal amphotericin B or micafungin at >or=5 mg/kg of body weight improved animal survival and suppressed the lung fungal burden for up to 7 days after infection, demonstrating the potential utility of infrequent dosing with these antifungals.

References

Oct 29, 2004·The Journal of Antimicrobial Chemotherapy·Jill P Adler-MooreRichard T Proffitt
May 13, 2005·Methods in Molecular Medicine·Russell E Lewis, Nathan P Wiederhold
Jan 31, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Parinda MehtaStella Davies
Jan 8, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J WalshUNKNOWN Infectious Diseases Society of America

❮ Previous
Next ❯

Citations

May 26, 2009·Revista iberoamericana de micología·Francisco Javier Pastor, Josep Guarro
May 5, 2010·Antimicrobial Agents and Chemotherapy·Thomas J WalshJohn E Conte
Jan 1, 2008·Infection and Drug Resistance·Nathan P WiederholdChristopher R Frei
Jul 9, 2014·Proceedings of the National Academy of Sciences of the United States of America·Pappanaicken R KumaresanLaurence J N Cooper
Feb 1, 2014·The Journal of Infection·D A EnochJ A Karas
May 28, 2016·The Journal of Antimicrobial Chemotherapy·Francesco BarchiesiEsther Manso
Sep 3, 2009·The Annals of Pharmacotherapy·Allana J SucherHolly E Balcer
May 17, 2019·Clinical Microbiology Reviews·Thomas LehrnbecherAndreas H Groll
Jun 22, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jill Adler-MooreThomas J Walsh
Mar 24, 2020·Current Fungal Infection Reports·Victoria M StevensTyree H Kiser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.